ICNMD 2021 poster: Ataluren delays loss of ambulation (LoA) and decline in pulmonary function in patients with nonsense mutation Duchenne muscular dystrophy (DMD)
This poster, presented at the ICNMD virtual meeting in 2021, shows the results from a study evaluating efficacy of a mutation-specific DMD therapy
Review the background, methods, and clinical characteristics of patients involved in a propensity score-matched study to evaluate the efficacy of a mutation-specific for DMD
Explore the Kaplan-Meier analysis of age at LoA for patients treated with a mutation-specific DMD therapy + standard of care (SoC) vs SoC alone
Review the comparison of age at milestones of pulmonary function decline in the 2 treatment populations
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200031 | March 2022
Sign in or register to access exclusive content on this site